Literature DB >> 19081414

Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy.

Olivier F Bertrand1, Eric Larose, Josep Rodés-Cabau, Onil Gleeton, Isabelle Taillon, Louis Roy, Paul Poirier, Olivier Costerousse, Robert De Larochellière.   

Abstract

BACKGROUND: Bleeding has recently emerged as predictor of early and late mortality after percutaneous coronary intervention (PCI) using femoral approach. Transradial PCI is associated with a lower risk of access-site complications than femoral approach. We evaluated the predictors of bleeding and the impact of major bleeding on death and major adverse cardiac events (MACE) after transradial PCI and maximal antiplatelet therapy.
METHODS: In the EASY (EArly discharge after transradial Stenting of coronarY arteries) trial, 1,348 patients with acute coronary syndrome were enrolled and underwent transradial PCI. All patients received clopidogrel (90% > or =12 hours pre-PCI) and a bolus of abciximab before first balloon inflation. Univariate and multivariate analyses to identify predictors and prognostic impact of major bleeding on death and MACE (death, myocardial infarction, and target vessel revascularization) were performed.
RESULTS: From the study population, 19 (1.4%) patients presented major bleeding. Patients with bleeding were older, had lower creatinine clearance, more often had 3-vessel disease and > or =3 dilated sites, and had longer procedures. Independent predictors of bleeding were creatinine clearance <60 mL/min (odds ratio [OR] 3.26, 95% confidence interval [CI] 1.10-8.67, P = .022), procedure duration (OR 2.95, 95% CI 1.12-8.31, P = .032), and sheath size (OR 5.34, 95% CI 1.44-34.65, P = .029). In patients with major bleeding, the incidence of MACE was higher at 30 days (37% vs 3%), 6 months (42% vs 8%), and 12 months (53% vs 12%; P < .0001 for all comparisons). By multivariate analysis, major bleeding was an independent predictive factor of 1-year mortality and MACE.
CONCLUSION: After transradial PCI and maximal antiplatelet therapy, the incidence of major bleeding remains low. Major bleeding is an independent predictive factor of adverse acute and 1-year outcomes, regardless of the access site.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19081414     DOI: 10.1016/j.ahj.2008.09.010

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

1.  The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.

Authors:  Vivian G Ng; Alexandra J Lansky; Stephanie Meller; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce Brodie; Ruchit Shah; Roxana Mehran; Gregg W Stone
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-10-03

2.  Identification and management of complications of transradial procedures.

Authors:  Adhir Shroff; Saifullah Siddiqui; Aaron Burg; Ish Singla
Journal:  Curr Cardiol Rep       Date:  2013-04       Impact factor: 2.931

3.  Impact of anemia on long-term ischemic events and bleeding events in patients undergoing percutaneous coronary intervention: a system review and meta-analysis.

Authors:  Xiaoyan Wang; Miaohan Qiu; Jing Qi; Jing Li; Heyang Wang; Yi Li; Yaling Han
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

4.  Rapid hemostasis at the femoral venous access site using a novel hemostatic pad containing kaolin after atrial fibrillation ablation.

Authors:  Akinori Sairaku; Yukiko Nakano; Noboru Oda; Yuko Makita; Kenta Kajihara; Takehito Tokuyama; Yasuki Kihara
Journal:  J Interv Card Electrophysiol       Date:  2011-02-19       Impact factor: 1.900

Review 5.  Clinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management.

Authors:  Magdalena Doktorova; Zuzana Motovska
Journal:  Crit Care       Date:  2013-09-27       Impact factor: 9.097

6.  Transulnar versus transradial approach for coronary angiography and angioplasty: Considering their complications.

Authors:  Farshad Roghani-Dehkordi; Rooholah Mansouri; Alireza Khosravi; Behzad Mahaki; Mehdi Akbarzadeh; Mohammad Kermani-Alghoraishi
Journal:  ARYA Atheroscler       Date:  2018-05

7.  Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis.

Authors:  Chun Shing Kwok; Sunil V Rao; Phyo K Myint; Bernard Keavney; James Nolan; Peter F Ludman; Mark A de Belder; Yoon K Loke; Mamas A Mamas
Journal:  Open Heart       Date:  2014-02-13

8.  Hemostasis pad combined with compression device after transradial coronary procedures: A randomized controlled trial.

Authors:  Si-Hyuck Kang; Donghoon Han; Sehun Kim; Chang-Hwan Yoon; Jin-Joo Park; Jung-Won Suh; Young-Seok Cho; Tae-Jin Youn; In-Ho Chae
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

9.  Incidence and predictors of forearm hematoma during the transradial approach for percutaneous coronary interventions.

Authors:  Naveen Garg; Koneru Lakshmi Umamaheswar; Aditya Kapoor; Satendra Tewari; Roopali Khanna; Sudeep Kumar; Pravin Kumar Goel
Journal:  Indian Heart J       Date:  2019-05-03

Review 10.  Update on Transradial Access for Percutaneous Transcatheter Visceral Artery Embolization.

Authors:  Hee Ho Chu; Jong Woo Kim; Ji Hoon Shin; Soo Buem Cho
Journal:  Korean J Radiol       Date:  2020-08-28       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.